Chief, Division of Hematology and Oncology Sr. Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy and Clinical Trials Office, UC San Diego Moores Cancer Center
Hematology
Dr. Razelle Kurzrock, MD
|
|
Give Review
Razelle Kurzrock is an expert in the field of Hematology. He received 1 awards: "Elected Member". Razelle Kurzrock is also published. He has 99 publications published. The lastest publication: "Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.'
Publications
- Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
- Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel deLivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
- Detection rate of actionable mutations in diverse Cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
- Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung Cancer.
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
- Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
- Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.
- NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
- Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced Melanoma.
- Phase I trial of valproic acid and lenalidomide in patients with advanced Cancer.
- HER2 expression status in diverse Cancers: review of results from 37,992 patients.
- Molecular landscape of pancreatic Cancer: implications for current clinical trials.
- P5.01A first in human, dose escalation trial of MSC2363318A - a dual p70S6K/Akt inhibitor, for patients with advanced malignancies.
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung Cancer.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Cyclin alterations in diverse Cancers: Outcome and co-amplification network.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
- Olanzapine for cachexia in patients with advanced Cancer: an exploratory study of effects on weight and metabolic cytokines.
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
- Targeted therapy for genetic Cancer syndromes: Fanconi anemia, medullary thyroid Cancer, tuberous sclerosis, and RASopathies.
- Targeted therapy for genetic Cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.
- Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung Cancer.
- Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with Systemic histiocytic disorders.
- Androgen receptors beyond prostate Cancer: an old marker as a new target.
- Targeted therapy for hereditary Cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.
- Targeted therapy for hereditary Cancer syndromes: hereditary breast and ovarian Cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
- Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities.
- Molecular aberrations, targeted therapy, and renal cell Carcinoma: current state-of-the-art.
- A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid Tumors.
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab.
- Targeted PI3K/AKT/mTOR therapy for metastatic Carcinomas of the cervix: A phase I clinical experience.
- BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid Cancer.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Outcomes of patients with advanced Cancer and KRAS mutations in phase I clinical trials.
- Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- U.s. Food and drug administration inspections of clinical investigators: overview of results from 1977 to 2009.
- Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid Tumors.
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- Characteristics and survival of patients with advanced Cancer and p53 mutations.
- BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study.
- First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid Tumors.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular Carcinoma using targeted next generation sequencing.
- Outcomes of patients with metastatic cervical Cancer in a phase I clinical trials program.
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- Erdheim-Chester Disease: Characteristics and Management.
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid Tumors.
- Evaluation of a novel blood pressure scoring method and its association with clinical response in Cancer patients treated with anti-vascular endothelial growth factor ...
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- Pediatric patients with refractory central Nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory Cancers: an open-label, phase 1 dose-escalation and expansion study.
- HER2 aberrations in Cancer: Implications for therapy.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced Cancers.
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced Cancer.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with ...
- NF2/Merlin in hereditary neurofibromatosis 2 versus Cancer: biologic mechanisms and clinical associations.
- Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with Liver metastases.
- A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on...
- Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved Cancer drugs.
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the Lung.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial.
- Equipoise abandoned? Randomization and clinical trials.
- Phase I Study of BIIB028, a Selective Heat Shock Protein 90 Inhibitor, in Patients with Refractory Metastatic or Locally Advanced Solid Tumors.
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Re...
- Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation.
- Posterior reversible encephalopathy syndrome: more than meets the eye.
- HER2-amplified salivary duct Carcinoma: Regression with dual HER2 inhibition and anti-VEGF combination treatment.
- Body composition and survival in the early clinical trials setting.
- A pilot study of temsirolimus and body composition.
- Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid Carcinoma on long-term RET inhibitor therapy.
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy.
- A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
- RE: Meta-Analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials.
- Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid Tumors.
- Compliance in early-phase Cancer clinical trials research.
- Factors related to biopsy willingness in patients with advanced Cancer in a phase 1 clinic for molecularly targeted therapy.
- BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for Analysis of acquired...
- Dodging a dogma: is treating beyond progression beneficial?
- Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical Carcinoma.
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
- Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel deLivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Procedures Preformed
- Prostate Cancer Screening Exam (DRE)
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Cigna
- Commercial Insurance Company
- HealthSmart
- Humana
- Medicare MCR
- United Healthcare
Awards
- Elected Member
Education
-
University of Texas MD Anderson Cancer Center -
Tulane University -
University of Toronto Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Similar Doctors
|
|
Dr. Luhua M. Wang, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Uday R. Popat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Selvarani Nallusamy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Powel H. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Loretta J. Nastoupil, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lance C. Pagliaro, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Guillermo Garcia-Manero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher B. Benton, MD |
|
|
Dr. Seung T. Lee, MD |
|
|
Dr. Mahesh Kanojia, MD |
|
|
Dr. Joe L. Moake, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Katayoun Rezvani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marguerite M. Rosales, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Annie R. Su, MD
This Doctor is OpenDoctor Recommended.
|